Thus, these probabilities define the gaps and differences between lines of SOFA ��5 for each cohort on each day.ResultsGlycemic control results for both cohorts were statistically different and are animal study presented in [21] along with detailed cohort and mortality data. Table Table22 presents admission and maximum SOFA scores, plus mortality data for the whole cohort across SOFA score. No statistically significant differences are seen due to low numbers, although raw mortality is lower in all but the very highest maximum SOFA score group. However, these are total cohort results, where the original study [19] only showed mortality differences for patients with ICU stay three days or longer.
Table 2Day 1 and maximum total SOFA score for each cohort plus percent mortality and number of patients (died, lived) by maximum SOFA score rangeFigure Figure11 presents the percentage of patients in each cohort with a total SOFA ��5 for each of the first 14 days, showing organ failure resolution over time. The clinical data are significantly different over the first 14 days (P = 0.016). This data is fitted with an exponential curve for clarity. The clinical data are statistically different between cohorts (P < 0.04) for the data over the first 21, 23, 25 and 28 days. Finally, Figure Figure22 shows the patient numbers per cohort by day, illustrating the relatively low patient numbers from Day 14 onward.Figure 1Percentage of patients with SOFA ��5 over each day (to 14 days). Exponential lines are fit to the data for clarity. Clinical data are significantly different (P ��0.001).
Modifying the lines to fit over 21, 23, 25 and 28 days yields very …Figure 2Patients remaining by day. At 14 days there are 67 Pre-SPRINT and 75 SPRINT patients remaining. The crossover in percentage of cohort remaining (not shown) is between Day 3 and Day 4.Figure Figure33 shows the mean and mean plus one standard deviation of SOFA score for both cohorts over the first 14 days. It is clear that there is divergence starting at Day 2. In particular, the mean plus one standard deviation line diverges to an increasingly lower value for the SPRINT cohort. This result may explain some of the clear divergence seen as early as two to four days in Figure Figure11.Figure 3Mean and Mean +1 SD lines for total SOFA score for the first 14 days for both cohorts.
By Days 3 and 4 there is a clear separation particularly for the mean + 1 SD values (P < 0.05).Figure Figure44 shows the daily trend of mean and mean plus one standard deviation of the total SOFA score for both cohorts split between survivors and non-survivors. As expected, survivors had lower SOFA scores throughout the time period (P < 0.01), and were similar or lower for SPRINT (P < 0.01).Figure Anacetrapib 4Mean and Mean + 1SD daily trend lines for survivors and non-survivors for both cohorts. Pre-SPRINT (top) and SPRINT (bottom).